Timothy B Lautz1, Yueh-Yun Chi2, Minjie Li3, Suzanne L Wolden4, Dana L Casey5, Jonathan C Routh6, Candace F Granberg7, Odion Binite8, Erin R Rudzinski9, Douglas S Hawkins10, Rajkumar Venkatramani11, David A Rodeberg12. 1. Department of Surgery, Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University, Chicago, Illinois. 2. Department of Pediatrics and Preventive Medicine, University of Southern California, Los Angeles, California. 3. Department of Biostatistics, University of Florida, Gainesville, Florida. 4. Division of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Division of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina. 6. Division of Urologic Surgery, Duke University School of Medicine, Durham, North Carolina. 7. Department of Urology, Mayo Clinic, Rochester, Minnesota. 8. Department of Orthopedic Surgery, Moffitt Cancer Center, Tampa, Florida. 9. Department of Pathology, Seattle Children's Hospital, University of Washington, Seattle, Washington. 10. Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington. 11. Division of Hematology/Oncology, Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas. 12. Division of Pediatric Surgery, Department of Surgery, East Carolina University, Greenville, North Carolina.
Abstract
BACKGROUND: Most children with intermediate-risk rhabdomyosarcoma (RMS) have gross disease (group III) at the initiation of chemotherapy. Delayed primary excision (DPE) after induction chemotherapy allows for a reduction in adjuvant radiation dose, but with the risk of potential surgical morbidity. The objectives of this study were to compare outcomes in children with group III RMS who did and did not undergo DPE and to assess surgical morbidity. METHODS: The study included 369 patients who had clinical group III RMS at sites amenable to DPE from intermediate-risk Children's Oncology Group studies D9803 (encouraged DPE) and ARST0531 (discouraged DPE). RESULTS: The primary tumor site was bladder/prostate (136 patients; 37%), extremity (97 patients; 26%), trunk (24 patients; 7%), retroperitoneum (91 patients; 25%), or intrathoracic/perineum/perianal (21 patients; 6%). In total, 112 patients (53.9%) underwent DPE in D9803, and 26 patients (16.2%) underwent DPE in ARST0531 (P < .001), with loss of vital organ or function in 30 of 138 patients (22%). DPE allowed for a reduced radiation dose in 110 of 135 patients (81%; 51% were reduced to 36 Gy, and 30% were reduced to 42 Gy). Patients who underwent DPE had improved unadjusted overall survival (P = .013). In adjusted regression analysis, the risk of death (hazard ratio, 0.71; 95% CI 0.43-1.16) was similar for patients who did and did not undergo DPE and was improved for the subset of patients who had tumors of the trunk and retroperitoneum (hazard ratio, 0.44; 95% CI, 0.20-0.97). CONCLUSIONS: Children with group III RMS have equivalent or improved outcomes with DPE and can receive a decreased radiation dose for definitive local control. The choice of local control modality should weigh the potential morbidity of surgery versus that of higher dose irradiation.
BACKGROUND: Most children with intermediate-risk rhabdomyosarcoma (RMS) have gross disease (group III) at the initiation of chemotherapy. Delayed primary excision (DPE) after induction chemotherapy allows for a reduction in adjuvant radiation dose, but with the risk of potential surgical morbidity. The objectives of this study were to compare outcomes in children with group III RMS who did and did not undergo DPE and to assess surgical morbidity. METHODS: The study included 369 patients who had clinical group III RMS at sites amenable to DPE from intermediate-risk Children's Oncology Group studies D9803 (encouraged DPE) and ARST0531 (discouraged DPE). RESULTS: The primary tumor site was bladder/prostate (136 patients; 37%), extremity (97 patients; 26%), trunk (24 patients; 7%), retroperitoneum (91 patients; 25%), or intrathoracic/perineum/perianal (21 patients; 6%). In total, 112 patients (53.9%) underwent DPE in D9803, and 26 patients (16.2%) underwent DPE in ARST0531 (P < .001), with loss of vital organ or function in 30 of 138 patients (22%). DPE allowed for a reduced radiation dose in 110 of 135 patients (81%; 51% were reduced to 36 Gy, and 30% were reduced to 42 Gy). Patients who underwent DPE had improved unadjusted overall survival (P = .013). In adjusted regression analysis, the risk of death (hazard ratio, 0.71; 95% CI 0.43-1.16) was similar for patients who did and did not undergo DPE and was improved for the subset of patients who had tumors of the trunk and retroperitoneum (hazard ratio, 0.44; 95% CI, 0.20-0.97). CONCLUSIONS: Children with group III RMS have equivalent or improved outcomes with DPE and can receive a decreased radiation dose for definitive local control. The choice of local control modality should weigh the potential morbidity of surgery versus that of higher dose irradiation.
Authors: R Beverly Raney; David O Walterhouse; Jane L Meza; Richard J Andrassy; John C Breneman; William M Crist; Harold M Maurer; William H Meyer; David M Parham; James R Anderson Journal: J Clin Oncol Date: 2011-02-28 Impact factor: 44.544
Authors: Sheri L Spunt; Teresa A Sweeney; Melissa M Hudson; Catherine A Billups; Matthew J Krasin; Allison L Hester Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Giovanni Cecchetto; Elena Carretto; Gianni Bisogno; Patrizia Dall'Igna; Andrea Ferrari; Giovanni Scarzello; Alberto Donfrancesco; Rita Alaggio; Paolo Indolfi; Modesto Carli Journal: Pediatr Blood Cancer Date: 2008-11 Impact factor: 3.167
Authors: R Heyn; V Haeberlen; W A Newton; A H Ragab; R B Raney; M Tefft; M Wharam; L G Ensign; H M Maurer Journal: J Clin Oncol Date: 1993-02 Impact factor: 44.544
Authors: Guido Seitz; Jörg Fuchs; Monika Sparber-Sauer; Ivo Leuschner; Jan Godzinski; Thomas Klingebiel; Andreas Schuck; Peter Martus; Tobias M Dantonello; Ewa Koscielniak Journal: Ann Surg Oncol Date: 2016-07-07 Impact factor: 5.344
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Toana Kawashima; Melissa M Hudson; Anna T Meadows; Debra L Friedman; Neyssa Marina; Wendy Hobbie; Nina S Kadan-Lottick; Cindy L Schwartz; Wendy Leisenring; Leslie L Robison Journal: N Engl J Med Date: 2006-10-12 Impact factor: 176.079
Authors: John T Lucas; Israel Fernandez-Pineda; Christopher L Tinkle; Michael W Bishop; Sue C Kaste; Rajiv Heda; Andrew M Davidoff; Matthew J Krasin Journal: Pract Radiat Oncol Date: 2017-04-26
Authors: Juri Fuchs; Anastasia Murtha-Lemekhova; Markus Kessler; Patrick Günther; Alexander Fichtner; Jan Pfeiffenberger; Pascal Probst; Katrin Hoffmann Journal: Front Oncol Date: 2021-09-30 Impact factor: 6.244